Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;25(9):992-1000.
doi: 10.5005/jp-journals-10071-23945.

Clinical Characteristics and Outcomes of COVID-19 Patients Hospitalized in Intensive Care Unit

Affiliations

Clinical Characteristics and Outcomes of COVID-19 Patients Hospitalized in Intensive Care Unit

Rahul A Pandit et al. Indian J Crit Care Med. 2021 Sep.

Abstract

Background: Meta-analysis and clinical studies suggest coronavirus disease-2019 (COVID-19) patients in ICU have a high mortality rate of 30-45%, which has evolved as a function of criteria of admission and the management modalities.

Materials and methods: We conducted a retrospective evaluation for characteristics and outcomes in critical care set up across six months.

Results: 514 patients (74.3% males and 25.6% females) were evaluated. 9.72% (n = 50) patients expired, 78% (n = 39) were males. Mean age (years) was 57 (±14, range 64, 95% CI 55-58). 65.7% (n = 338) were of age more than 50 years, of which 71.5% (n = 242) were males. Males at 20% higher risk for death than women. (RR = 1.2, 95% CI 0.66-2.31, p = 0.61 NS). There was 18% less risk of mortality in female vs male with comorbidities (RR 0.82, 95% CI 0.67-1.12, p = 0.32 NS). Risk for mortality in diabetics was significantly increased by 116% vs nondiabetics. (RR 2.16, p = 0.0055, 95% CI 1.28-3.67). Highly significant risk of mortality in age group >50 years (3.13 times higher) vs age ≤50 years. (RR 3.18, 95% CI 1.71-8.64, p = 0.0003). 50.2% had moderate ARDS at admission. High flow nasal cannula was used in 47.2%. There is 5.79 times more likelihood to be on the ventilator with moderate to severe ARDS vs mild ARDS (RR = 5.79, 95% CI 3.10-11.05, p <0.0001). Risk for death was six times higher for patients on ventilator vs not on ventilator (RR = 6.08, 95% CI 3.49-10.59, p <0.0001). The mean number of days on ventilator for patients who underwent tracheostomy (n = 49) was 14 days as compared to 6.6 days in patients who were extubated (n = 57) (p <0.0001). P/F ratio had negative correlation with number of days of hospitalisation (Pearson r -0.391, 95% CI -0.46- -0.31, p <0.0001). 67% less chances of mortality in patients on steroids (RR = 0.33, 95% CI 0.19-60, p = 0.0012). Mean duration of ICU stay (days) was 8 (± 5, range 29, 95% CI 7.5-8.4).

Conclusions: We observed that a strict adherence to the basic principles of ARDS management resulted in a lower mortality in ICU setting.

How to cite this article: Pandit RA, Gagana BN, Vaity C, Mulakavalupil B, Choudhary JS, Jain V, et al. Clinical Characteristics and Outcomes of COVID-19 Patients Hospitalized in Intensive Care Unit. Indian J Crit Care Med 2021;25(9):992-1000.

Keywords: COVID-19; ICU; Outcomes.

PubMed Disclaimer

Conflict of interest statement

Source of support: Nil Conflict of interest: None

Figures

Fig. 1
Fig. 1
Different oxygenation methods across the cohort
Fig. 2
Fig. 2
Different oxygenation methods across the cohort with moderate-severe ARDS and mild ARDS
Fig. 3
Fig. 3
Ventilator across diabetics and nondiabetics
Fig. 4
Fig. 4
Comparison of the mortality based on the number of days on the ventilator
Fig. 5
Fig. 5
Difference in ICU days of the patients on ventilator support
Fig. 6
Fig. 6
Course among ventilated patients
Fig. 7
Fig. 7
Difference between the number of days on ventilator and tracheostomy
Fig. 8
Fig. 8
Difference between the mortality and the number of days in ICU
Flowchart 1
Flowchart 1
Simple linear regression of correlation between P/F ratio and ICU days

References

    1. Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, et al. Management of hospitalised adults with coronavirus disease-19 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021;57(4):2100048. doi: 10.1183/13993003.00048-2021. DOI: - DOI - PMC - PubMed
    1. Sarma P, Bhattacharyya A, Kaur H, Prajapat M, Prakash A, Kumar S, et al. Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis. Indian J Pharmacol. 2020;52(6):535–550. doi: 10.4103/ijp.ijp_1146_20. DOI: - DOI - PMC - PubMed
    1. Zhan Y, Shang J, Gu Y, Huang Q, Xie J. Efficacy of corticosteroid in patients with COVID-19: a multi-center retrospective study and meta-analysis. J Med Virol. 2021;93(7):4292–4302. doi: 10.1002/jmv.26914. DOI: - DOI - PMC - PubMed
    1. Macedo A, Gonçalves N, Febra C. COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis. Ann Epidemiol. 2021;57:14–21. doi: 10.1016/j.annepidem.2021.02.012. DOI: - DOI - PMC - PubMed
    1. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin definition. 2012;307(23):2526–2533. doi: 10.1001/jama.2012.5669. JAMA. DOI: - DOI - PubMed

LinkOut - more resources